Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight

The nontuberculous mycobacterial infections Market is expected to experience notable growth in the coming years, driven by the increasing prevalence and improved diagnosis of NTM infections, particularly among aging populations and individuals with underlying respiratory conditions. Additionally, the expected launch of emerging therapies such as Omadacycline (NUZYRA; Paratek Pharmaceuticals), MRX-5 (MicuRx Pharmaceuticals), Epetraborole (AN2 Therapeutics), RHB-204 (Redhill Biopharma), and others will further propel market growth.

New York, USA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight

The nontuberculous mycobacterial infections Market is expected to experience notable growth in the coming years, driven by the increasing prevalence and improved diagnosis of NTM infections, particularly among aging populations and individuals with underlying respiratory conditions. Additionally, the expected launch of emerging therapies such as Omadacycline (NUZYRA; Paratek Pharmaceuticals), MRX-5 (MicuRx Pharmaceuticals), Epetraborole (AN2 Therapeutics), RHB-204 (Redhill Biopharma), and others will further propel market growth.

Recently published Nontuberculous Mycobacterial Infections Market Insights report includes a comprehensive understanding of current treatment practices, nontuberculous mycobacterial infections emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Nontuberculous Mycobacterial Infections Market Summary

• The market size for nontuberculous mycobacterial infections was found to be USD 750 million in the 7MM in 2025.
• The United States accounted for the largest nontuberculous mycobacterial infections treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In 2025, the total number of diagnosed prevalent cases of NTM in the 7MM was around 400,000. Among the 7MM countries, the US accounted for the highest number of diagnosed prevalent cases.
• Key nontuberculous mycobacterial infections companies, including Paratek Pharmaceuticals, MicuRx Pharmaceuticals, AN2 Therapeutics, Redhill Biopharma, LigaChem Biosciences, Vast Therapeutics, Crestone, Inc., and others, are actively working on innovative nontuberculous mycobacterial infections drugs. 
• Some of the key nontuberculous mycobacterial infections therapies in clinical trials include Omadacycline (NUZYRA), MRX-5, Epetraborole, RHB-204, Delpazolid (LCB01-0371), ALX1, CRS0393, and others. These novel nontuberculous mycobacterial infections therapies are anticipated to enter the nontuberculous mycobacterial infections market in the forecast period and are expected to change the market.

Discover more about the NTM infections market @ https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-ntm-infections-market

Key Factors Driving the Growth of the Nontuberculous Mycobacterial Infections Market 

• Rising Prevalence and Improved Disease Recognition: Increasing awareness and improved diagnostic capabilities are contributing to the identification of more NTM infection cases. The growing prevalence, particularly among vulnerable and aging populations, is expanding the patient pool requiring treatment.
• ARIKAYCE’s First-Mover Advantage: The approval of ARIKAYCE as the first and only disease-specific therapy for treatment-refractory MAC-NTM lung disease validated NTM as a clinically and commercially attractive therapeutic area while establishing a strong first-mover advantage.
• Advancements in Diagnostic Technologies: The adoption of molecular diagnostics, advanced imaging, and improved microbiological testing is enabling earlier and more accurate detection of NTM infections. Better diagnosis is helping differentiate NTM from tuberculosis and other respiratory diseases, supporting timely treatment.
• Launch of Emerging Medication for Nontuberculous Mycobacterial Infections: The dynamics of the NTM infections market are expected to change in the coming years due to the launch of emerging therapies such as Omadacycline (NUZYRA; Paratek Pharmaceuticals), MRX-5 (MicuRx Pharmaceuticals), Epetraborole (AN2 Therapeutics), RHB-204 (Redhill Biopharma), Delpazolid (LCB01-0371; LigaChem Biosciences), ALX1 (Vast Therapeutics), CRS0393 (Crestone, Inc.), and others.

Aparna Thakur, project manager of forecasting at DelveInsight, stated that among the emerging therapies, omadacycline (NUZYRA; Paratek Pharmaceuticals) is the only investigational therapy in active Phase II clinical development. The drug is being evaluated for M. abscessus pulmonary disease and represents the most advanced emerging candidate with the potential to address the unmet need for safer, orally administered treatment options. 

Nontuberculous Mycobacterial Infections Market Analysis

• The NTM treatment landscape is likely to advance through species-specific therapeutic innovation rather than direct competition among products. 
• ARIKAYCE is expected to maintain its position as a key therapy for refractory MAC-associated NTM pulmonary disease, supported by its established clinical role and the absence of direct competitors targeting this patient population. Its targeted inhalation-based delivery and continued adoption are expected to reinforce its presence in the marketed treatment landscape.
• Meanwhile, NUZYRA, if approved, could help address the significant unmet need in Mycobacterium abscessus infections as a potential first-line monotherapy. This reflects a broader shift toward pathogen-specific treatment strategies and the expansion of therapeutic options beyond MAC disease.
• An aging population and the growing prevalence of conditions such as bronchiectasis, COPD, and cystic fibrosis, which increase susceptibility to NTM colonization, are expected to expand the addressable patient population. 
• From a commercial perspective, these demographic and epidemiological trends could create a growing opportunity for therapies entering the NTM market.
• Despite these opportunities, the NTM pipeline remains relatively limited, with few late-stage, pathogen-specific therapies positioned to replace existing prolonged multidrug treatment regimens. 
• Most emerging therapies are being developed as adjunctive options rather than curative alternatives, underscoring the need for novel treatments with broader species coverage, improved efficacy and tolerability, and the potential to shorten treatment duration.

Learn more about the nontuberculous mycobacterial infections therapeutics market @ Medication for Nontuberculous Mycobacterial Infections 

Nontuberculous Mycobacterial Infections Competitive Landscape

Some of the medication for nontuberculous mycobacterial infections treatment under development include Omadacycline (NUZYRA; Paratek Pharmaceuticals), MRX-5 (MicuRx Pharmaceuticals), Epetraborole (AN2 Therapeutics), RHB-204 (Redhill Biopharma), Delpazolid (LCB01-0371; LigaChem Biosciences), ALX1 (Vast Therapeutics), CRS0393 (Crestone, Inc.), and others.

Paratek Pharmaceuticals’ NUZYRA is a next-generation tetracycline antibiotic currently being evaluated in a Phase II clinical program for the treatment of Mycobacterium abscessus complex (MABc)-associated NTM pulmonary disease. Designed to address tetracycline resistance, NUZYRA has demonstrated broad antibacterial activity against gram-positive, gram-negative, atypical, and other drug-resistant pathogens. In November 2024, Paratek Pharmaceuticals reported positive topline results from its Phase IIb trial assessing NUZYRA in adults with NTM pulmonary disease caused by MABc.

Redhill Biopharma’s RHB-204 is an investigational, proprietary, fixed-dose oral antibiotic combination being developed for the treatment of Crohn’s disease in patients who test positive for Mycobacterium avium subspecies paratuberculosis (MAP+). As a next-generation version of RedHill’s RHB-104, RHB-204 builds on the earlier formulation, which achieved positive results in a Phase III Crohn’s disease trial by meeting both its primary and secondary endpoints. While incorporating the same antimicrobial agents as RHB-104, RHB-204 features an optimized dosing regimen intended to improve tolerability, safety, and patient adherence, while retaining potent intracellular antimycobacterial and anti-inflammatory activity. Beyond Crohn’s disease, RHB-204 may also have potential in treating pulmonary nontuberculous mycobacterial (NTM) disease caused by Mycobacterium avium complex (MAC).

Meanwhile, Crestone is advancing a new class of antimycobacterial compounds known as benzothiazole amides, designed to inhibit the MmpL3 protein, which plays a critical role in mycobacterial cell wall synthesis. Through its collaboration with researchers at Colorado State University, the company’s hit-to-lead program has identified CRS0393, an advanced candidate demonstrating strong activity against a broad range of tested mycobacteria, including multidrug-resistant strains.

The anticipated launch of these emerging nontuberculous mycobacterial infections therapies are poised to transform the nontuberculous mycobacterial infections market landscape in the coming years. As these cutting-edge nontuberculous mycobacterial infections therapies continue to mature and gain regulatory approval, they are expected to reshape the nontuberculous mycobacterial infections market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about nontuberculous mycobacterial infections treatment options, visit @ Nontuberculous Mycobacterial Infections Therapeutic Market

Recent Developments in the Nontuberculous Mycobacterial Infections Market

• In January 2026, MicuRx Pharmaceuticals, Inc. announced that the U.S. FDA has cleared its Investigational New Drug (IND) application for MRX-5, paving the way for the company to launch a Phase 2a clinical trial in patients with Mycobacterium abscessus pulmonary disease.
• In October 2025, Paratek Pharmaceuticals announced that new clinical data for NUZYRA was presented at IDWeek 2025 and CHEST 2025, including microbiological findings from a Phase II study evaluating the therapy in patients with NTM-PD caused by MABc.
• In May 2025, Paratek Pharmaceuticals reported that clinical data for NUZYRA was presented at the American Thoracic Society (ATS) 2025 International Conference and ESCMID Global 2025 in April 2025, including first presentations from a Phase IIb study in patients with NTM-PD caused by MABc.

Nontuberculous Mycobacterial Infections Epidemiology Segmentation

The nontuberculous mycobacterial infections epidemiology section provides insights into the historical and current nontuberculous mycobacterial infections patient pool and forecasted trends for the leading markets. Pulmonary NTM infections represented the predominant clinical presentation across the 7MM in 2025, accounting for ~340,000 diagnosed cases.

The NTM infections market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:

• Total Diagnosed Prevalent Cases of NTM Infections
• Gender-specific Diagnosed Prevalent Cases of NTM Infections
• Species-specific Diagnosed Prevalent Cases of NTM Infections
• Severity-specific Diagnosed Prevalent Cases of NTM Infections
• Type-specific Diagnosed Prevalent Cases of NTM Infections
• Total Treated Cases of NTM Infections
• Refractory Cases of NTM Infections

Download the report to understand the future of nontuberculous mycobacterial infections treatment @ Nontuberculous Mycobacterial Infections Drugs

Nontuberculous Mycobacterial Infections Market Report Metrics	Details
Study Period	2022–2036
Nontuberculous Mycobacterial Infections Market Report Coverage	7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Nontuberculous Mycobacterial Infections Market CAGR (2022–2036)	12.6%
Nontuberculous Mycobacterial Infections Market Size in 2025	USD 750 Million
Key Nontuberculous Mycobacterial Infections Companies	Paratek Pharmaceuticals, MicuRx Pharmaceuticals, AN2 Therapeutics, Redhill Biopharma, LigaChem Biosciences, Vast Therapeutics, Crestone, Inc., Insmed, and others
Key Nontuberculous Mycobacterial Infections Therapies	Omadacycline (NUZYRA), MRX-5, Epetraborole, RHB-204, Delpazolid (LCB01-0371), ALX1, CRS0393, ARIKAYCE, and others

Scope of the Nontuberculous Mycobacterial Infections Market Report

• Nontuberculous Mycobacterial Infections Patient Population Forecast
• Nontuberculous Mycobacterial Infections Therapeutics Market Size
• Nontuberculous Mycobacterial Infections Pipeline Analysis
• Nontuberculous Mycobacterial Infections Market Size and Trends
• Nontuberculous Mycobacterial Infections Market Opportunity
• Nontuberculous Mycobacterial Infections Market Unmet Needs
• KOL’s Views on Nontuberculous Mycobacterial Infections
• Nontuberculous Mycobacterial Infections Market Access and Reimbursement

Discover more about next-generation NTM infections drugs @ Nontuberculous Mycobacterial Infections Clinical Trials

Table of Contents

1	Nontuberculous Mycobacterial Infections Market Key Insights
2	Nontuberculous Mycobacterial Infections Market Report Introduction
3	NTM Infections Market Overview at a Glance
3.1	Market Share (%) Distribution of NTM Infections by Therapies in the 7MM in 2025
3.2	Market Share (%) Distribution of NTM Infections by Therapies in the 7MM in 2036
4	Executive Summary of NTM Infections
5	Key Events
6	Disease Background and Overview: NTM Infections
6.1	Introduction
6.2	Classification
6.3	Sign and Symptoms
6.4	Risk Factors
6.5	Pathophysiology
6.6	Diagnosis
6.7	Diagnostic Guidelines
6.8	Treatment and Management
6.9	Treatment Guidelines
7	Epidemiology and Market Forecast Methodology
8	Epidemiology and Patient Population
8.1	Key Findings on Patient Burden in NTM Infections
8.2	Assumptions and Rationale
8.2.1	Prevalent Cases of NTM Infections
8.2.2	Diagnosed Prevalent Cases of NTM Infections
8.2.3	Gender-specific Rate of NTM Infections
8.2.4	Species-specific Rate of NTM Infections
8.2.5	Severity-specific Rate of NTM Infections
8.2.6	Type-specific Rate of NTM Infections
8.3	Total Diagnosed Prevalent Cases of NTM Infections in the 7MM
8.4	The US
8.4.1	Total Diagnosed Prevalent Cases of NTM Infections in the US
8.4.2	Gender-specific Diagnosed Prevalent Cases of NTM Infections in the US
8.4.3	Species-specific Diagnosed Prevalent Cases of NTM Infections in the US
8.4.4	Severity-specific Diagnosed Prevalent Cases of NTM Infections in the US
8.4.5	Type-specific Diagnosed Prevalent Cases of NTM Infections in the US
8.4.6	Total Treated Cases of NTM Infections in the US
8.4.7	Refractory Cases of NTM Infections in the US
8.5	EU4 and the UK
8.6	Japan
9	Patient Journey: NTM infections
10	Marketed NTM Infections Drugs
10.1	Amikacin Liposome Inhalation Suspension (ARIKAYCE): Insmed
10.1.1	Product Description
10.1.2	Regulatory Milestones
10.1.3	Other Developmental Activities
10.1.4	Summary of Pivotal Trials
10.1.5	Clinical Development
10.1.5.1	Clinical Trial Information
10.1.6	Analyst views
To be continued in the report…
11	Emerging NTM Infection Drugs
11.1	Competitive Landscape: Emerging Drugs
11.2	Omadacycline (NUZYRA): Paratek Pharmaceuticals
11.2.1	Drug Description
11.2.2	Other Developmental Activities
11.2.3	Clinical Development Activity
11.2.4	Safety and efficacy
11.2.5	Analyst Views
To be continued in the report…
12	NTM Infections Market – The 7MM Market Analysis
12.1	NTM Infections Market Key Findings and Insights
12.2	Key Nontuberculous Mycobacterial Infections Market Forecast Assumptions
12.3	Nontuberculous Mycobacterial Infections Market Outlook
12.4	Attribute Analysis
12.5	Market Size of NTM Infections in the 7MM
12.6	Market Size of NTM Infections by Therapies in the 7MM
12.7	The United States Nontuberculous Mycobacterial Infections Market Size
12.7.1	Total Market Size of NTM Infections in the US
12.7.2	Market Size of NTM Infections by Therapies in the US
12.8	EU4 and the UK Nontuberculous Mycobacterial Infections Market Size
12.9	Japan Nontuberculous Mycobacterial Infections Market Size
13	Key Opinion Leaders’ Views
14	Unmet Needs
15	SWOT Analysis
16	Nontuberculous Mycobacterial Infections Market Access and Reimbursement
16.1	The United States
16.2	In EU4 and the UK
16.3	Japan
16.4	Summary and Comparison of Market Access and Pricing Policy Developments in 2025
16.5	Market Access and Reimbursement of NTM Infections
17	Bibliography
18	Nontuberculous Mycobacterial Infections Market Report Methodology

Related Reports

Nontuberculous Mycobacterial Infection Clinical Trial Analysis 

Nontuberculous Mycobacterial Infection Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nontuberculous mycobacterial infection companies, including Mannkind Corporation, Matinas BioPharma, Spero Therapeutics, Crestone, Inc, Vast Therapeutics, and others.

MAC Lung Disease Market

MAC Lung Disease Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key MAC lung disease companies including Mannkind Corporation, Johnson and Johnson (Janssen Pharmaceutical K.K.), Spero Therapeutics, and others.

Chronic Obstructive Pulmonary Disease Market

Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key chronic obstructive pulmonary disease companies, including Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, Tetherex Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., Pulmatrix, Glenmark Pharmaceuticals Ltd, Dimerix Limited, ProterixBio, and others.

Asthma Market

Asthma Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key asthma companies including GlaxoSmithKline, 4D Pharma plc, AstraZeneca, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Sinomab, Avalo Therapeutics, Kymab, Sanofi, Cumberland Pharmaceuticals, Genentech, Inc., and others.

Severe Asthma Market

Severe Asthma Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key severe asthma companies, including AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Inc., Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb, Eli Lilly and Company, Vertex Pharmaceuticals Incorporated, Amgen Inc., AbbVie Inc., Genentech, Inc., Gilead Sciences, Inc., Biogen Inc., CSL Limited, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679